• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BrainsWay Ltd. (Amendment)

    2/14/24 7:34:04 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care
    Get the next $BWAY alert in real time by email
    SC 13G/A 1 p24-0393sc13ga.htm BRAINSWAY LTD.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
     
    SCHEDULE 13G/A
     
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  4)*
     

    BrainsWay Ltd.

    (Name of Issuer)
     

    Ordinary Shares, par value NIS 0.04 per share

    (Title of Class of Securities)
     

    10501L106**

    (CUSIP Number)
     

    December 31, 2023

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G/A is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    **There is no CUSIP number assigned to the Shares. CUSIP number 10501L106 has been assigned to the American Depositary Shares ("ADS") of the Company, which are quoted on the Nasdaq Global Market under the symbol "BWAY." Each ADS represents 2 Shares.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 10501L10613G/APage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. 10501L10613G/APage 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong, M.D.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. 10501L10613G/APage 4 of 7 Pages

     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is BrainsWay Ltd. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 19 Hartum Street, Brynet Building, 3rd Floor, Har HaHotzvim, Jerusalem, 9777518, Israel.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by:

     

      (i) RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) that were directly held by the RTW Funds; and
         
      (ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares that were directly held by the RTW Funds.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:

     

      RTW Investments is a Delaware limited partnership.  Dr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Ordinary Shares, par value NIS 0.04 per share (the "Shares").

     

     

    CUSIP No. 10501L10613G/APage 5 of 7 Pages

     

    Item 2(e). CUSIP NUMBER:
       
      There is no CUSIP number assigned to the Shares.  CUSIP number 10501L106 has been assigned to the ADSs.

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                                   

     

    Item 4. OWNERSHIP:

     

        The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

     

    CUSIP No. 10501L10613G/APage 6 of 7 Pages

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following:  ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 10501L10613G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    DATED:  February 14, 2024
     
    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong, M.D.  
    Name: Roderick Wong, M.D.  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong, M.D.  
    RODERICK WONG, M.D.  
         

     

     

     

    Get the next $BWAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BWAY

    DatePrice TargetRatingAnalyst
    11/16/2023Outperform → Mkt Perform
    Raymond James
    3/3/2022$15.00Buy
    Loop Capital
    11/29/2021$14.00 → $15.00Buy
    HC Wainwright & Co.
    8/12/2021$17.00 → $14.00Buy
    HC Wainwright & Co.
    7/19/2021$17.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BWAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Association Annual Meeting in Los Angeles

      BURLINGTON, Mass. and JERUSALEM, May 01, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its participation at the American Psychiatric Association (APA) Annual Meeting, taking place May 17–21, 2025, in Los Angeles, California. As part of the meeting's educational programming, there will be a full day master course on Sunday, May 18, 2025, entitled: "Clinical Applications for Psychiatric Practice: Ketamine and TMS." The course will provide an in-depth look at the integration of novel treatments into clinical psychiatric practice, highlighting practical approa

      5/1/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025

      BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, May 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time the same day to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, May 13, 2025Time:8:30 AM Eastern TimeUnited States:1-877-300

      4/29/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth qua

      3/11/25 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

      SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

      11/14/24 1:33:58 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

      SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

      11/14/24 1:32:48 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by BrainsWay Ltd.

      SC 13D - Brainsway Ltd. (0001505065) (Subject)

      11/13/24 6:09:51 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    SEC Filings

    See more

    $BWAY
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form 424B3 filed by BrainsWay Ltd.

      424B3 - Brainsway Ltd. (0001505065) (Filer)

      5/1/25 7:00:47 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by BrainsWay Ltd.

      EFFECT - Brainsway Ltd. (0001505065) (Filer)

      5/1/25 12:15:26 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • SEC Form F-3 filed by BrainsWay Ltd.

      F-3 - Brainsway Ltd. (0001505065) (Filer)

      4/22/25 4:05:48 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer

      BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer (CMO), effective September 1, 2024. Dr. Aron Tendler, M.D., who has served as CMO since 2015, will continue to serve as a collaborator on important strategic research projects. "We are excited to have Richard join our team to lead and shape BrainsWay's clinical strategy and product roadmap. His extensive experience with TMS and brain stimulation therapies as a practicing phys

      8/29/24 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • Murchinson Takes Action to Replace Board of Directors of Nano Dimension at Upcoming Annual General Meeting

      Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th

      8/3/23 3:00:00 PM ET
      $BWAY
      $INSG
      $MCK
      $NNDM
      Medical/Dental Instruments
      Health Care
      Telecommunications Equipment
      Telecommunications
    • BrainsWay Announces Appointment of Ido Marom as CFO

      BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Ido Marom, an experienced senior financial leader in global industries, including medical technology, as Chief Financial Officer (CFO). Mr. Marom will succeed Scott Areglado, who will be stepping down from the Company to pursue other opportunities. "We are thrilled to welcome Ido and his extensive financial expertise to BrainsWay," stated Hadar Levy, BrainsWay's Chief Executive Officer. "He has led the financial strategy and i

      5/23/23 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brainsway downgraded by Raymond James

      Raymond James downgraded Brainsway from Outperform to Mkt Perform

      11/16/23 7:31:55 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • Loop Capital initiated coverage on BrainsWay with a new price target

      Loop Capital initiated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00

      3/3/22 4:42:28 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on BrainsWay with a new price target

      HC Wainwright & Co. reiterated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00 from $14.00 previously

      11/29/21 6:24:14 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Financials

    Live finance-specific insights

    See more
    • BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025

      BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, May 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time the same day to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, May 13, 2025Time:8:30 AM Eastern TimeUnited States:1-877-300

      4/29/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth qua

      3/11/25 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

      BURLINGTON, Mass. and JERUSALEM, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2024 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, March 11, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, March 11, 2025Time:8:30 AM Eastern TimeUnited

      2/24/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care